C31G oral rinse

Drug Profile

C31G oral rinse

Alternative Names: 0.5% C31G oral rinse; 0.5% glyminox; Oramed

Latest Information Update: 07 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biosyn
  • Class
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Candidiasis

Most Recent Events

  • 31 Dec 2006 Discontinued - Phase-I/II for Candidiasis in USA (PO)
  • 15 Dec 2004 Biosyn has been acquired by Cellegy Pharmaceuticals
  • 12 Oct 2004 Cellegy Pharmaceuticals has entered into a definitive agreement to acquire Biosyn
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top